These findings underscore the effect of Nras point mutations in driving divergent HCC models, further singularizing NrasG12D-driven HCC as a distinct aggressive model compared to MycOE-associated liver tumors. The gene discussed is NRAS; the disease is hepatocellular carcinoma.